Finance

Lists
Outlook: 66.7% bullish·0.0% bearish
Go to analysis
ACRS:NASDAQ
Aclaris Therapeutics Inc
3,97 US$
-0,50%
(-0,020) 1D
4,03 US$
+1,51% (+0,060)
After hours
Closed: 30 ოქტ, 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ACRS...
Open
4,00 US$
High
4,07 US$
Low
3,87 US$
Mkt. cap
586,01 მლნ.
Avg. vol.
3,63 მლნ.
Volume
1,88 მლნ.
52-wk high
6,60 US$
52-wk low
2,10 US$
EPS
-0,59 US$
Beta
0,87
Shares outstanding
147,20 მლნ.
No. of employees
71
Open
4,00 US$
High
4,07 US$
Low
3,87 US$
Mkt. cap
586,01 მლნ.
Avg. vol.
3,63 მლნ.
Volume
1,88 მლნ.
52-wk high
6,60 US$
52-wk low
2,10 US$
EPS
-0,59 US$
Beta
0,87
Shares outstanding
147,20 მლნ.
No. of employees
71
News stories
From web sources and news partners
The Business Journals
The Business Journals
·
1 დღის წინ
Wayne company raises $50M to fund drug development
About Aclaris Therapeutics Inc
CEO-
Employees71
Founded2012
Headquarters-
SectorPharmaceutical industry
Analyst ratings
Based on 7 analysts giving stock ratings to ACRS in the past 3 months
Strong buy
Buy
7
Hold
0
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for ACRS in the last 3 months.
Highest
Current 3,97 US$
16,00 US$ (+303,02%)
Average
12,00 US$ (+202,27%)
Lowest
9,00 US$ (+126,70%)
Analyst
Recommendation
Action
Price target
Projected
Date
Edward Nash
Canaccord Genuity
Buy
Reiterated
13,00 US$
+227,5%
10/30/2026
Seamus Fernandez
Guggenheim
Buy
Reiterated
12,00 US$
+202,3%
10/28/2026
Adam Vogel
Craig-Hallum
Buy
Maintained
9,00 US$
+126,7%
10/28/2026
Unknown Analyst
Oppenheimer
Buy
Reiterated
10,00 US$
+151,9%
10/28/2026
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
16,00 US$
+303%
10/28/2026
Biren Amin
Piper Sandler
Buy
Maintained
11,00 US$
+177,1%
10/19/2026
Kate Dellorusso
LifeSci Capital
Buy
Maintained
13,00 US$
+227,5%
10/01/2026
Martin Fan
Wedbush
Buy
Maintained
10,00 US$
+151,9%
05/08/2026
Jeff Jones
Oppenheimer
Buy
Reiterated
10,00 US$
+151,9%
05/08/2026
Alex Thompson CFA
Stifel Nicolaus
Hold
Maintained
4,00 US$
+0,8%
05/08/2026
Unknown Analyst
Goldman Sachs
Buy
Maintained
10,00 US$
+151,9%
04/16/2026
Next call 7 დღეში
პარ, 6 ნოე, 19:30
Fiscal period
Q3 2026
- / -0,16 US$
Revenue / Est. (USD)
- / 1,23 მლნ.
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
3,30 მლნ.
1,30 მლნ.
2,00 მლნ.
1,63 მლნ.
Cost of goods sold
15,48 მლნ.
18,05 მლნ.
17,44 მლნ.
19,52 მლნ.
Cost of revenue
15,48 მლნ.
18,05 მლნ.
17,44 მლნ.
19,52 მლნ.
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4,87 მლნ.
5,58 მლნ.
6,74 მლნ.
6,05 მლნ.
Operating expense
4,87 მლნ.
5,58 მლნ.
6,74 მლნ.
6,05 მლნ.
Total operating expenses
20,35 მლნ.
23,63 მლნ.
24,19 მლნ.
25,57 მლნ.
Operating income
-17,05 მლნ.
-22,33 მლნ.
-22,19 მლნ.
-23,94 მლნ.
Other non operating income
716,00 ათ.
1,30 მლნ.
854,00 ათ.
972,00 ათ.
EBT including unusual items
-14,61 მლნ.
-19,80 მლნ.
-19,82 მლნ.
-21,50 მლნ.
EBT excluding unusual items
-14,51 მლნ.
-19,40 მლნ.
-19,82 მლნ.
-21,20 მლნ.
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-14,61 მლნ.
-19,80 მლნ.
-19,82 მლნ.
-21,50 მლნ.
Net profit margin
-442,98%
-1 528,57%
-993,19%
-1 320,13%
Earnings per share
-0,12
-0,16
-0,15
-0,15
Interest and investment income
1,82 მლნ.
1,63 მლნ.
1,51 მლნ.
1,76 მლნ.
Interest expense
-
-
-
-
Net interest expenses
1,82 მლნ.
1,63 მლნ.
1,51 მლნ.
1,76 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-17,04 მლნ.
-22,32 მლნ.
-22,19 მლნ.
-23,94 მლნ.
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google აპები